Recently, the results of 2023 Venture50, initiated by Zero2IPO Group and Investment Community, were finally announced! Tsingke, with its excellent technology research and development strength in biosynthesis, good market performance and excellent development potential, has been selected among many participating companies and has been honored to be on the Venture50 list.
Venture50 was founded by Zero2IPO Group in 2006, and after 18 years of development, it has become the wind vane of China's high-growth enterprise investment value. This year, it has set up five industry lists, including life and health, and selected 50 unlisted companies with the significance of industry wind vane.
The list is evaluated by more than 100 judges from first-tier investment institutions, and after 5 months of selection, comparison, research and visits, the list is comprehensively rated from a professional investment perspective. As of October 2023, there are more than 75,000 participating companies.
The inclusion in the Venture50 list is not only a recognition of Tsingke's science and technology-oriented, digital empowerment, and intelligent innovation in the field of life and health, but also reflects that Tsingke has received a high degree of recognition from the venture capital community in terms of its investment value and development potential.
Tsingke takes "The great Tsingke gene factory" as its corporate vision, continues to adhere to the independent research and development of core technologies, and contributes more power to the upgrading and optimization of the life and health industry.
